Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100

Thermo Fisher Scientific Inc. (TMO) Net income

Alert me on Net income

Thermo Fisher Scientific Inc.'s net income for fiscal 2025 was $6.7B, up 6.04% from $6.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $7.0B. Over the past ten years it has ranged from $2.0B (fiscal 2015) to $7.7B (fiscal 2021); the current reading is higher than 82% of that period. Thermo Fisher Scientific Inc. ranks 1st of 52 Diagnostics & Research companies by net income.

Net income, annual

Embed this chart

Annual newest first

Period Net income Change
FY2025 $6.7B 6.04%
FY2024 $6.3B 6.43%
FY2023 $6.0B (14.44%)
FY2022 $7.0B (9.94%)
FY2021 $7.7B 21.19%
FY2020 $6.4B 72.44%
FY2019 $3.7B 25.87%
FY2018 $2.9B 32.04%
FY2017 $2.2B 10.04%
FY2016 $2.0B 2.38%

Quarterly newest first

Period Net income Change
Jun 2026 $1.7B 5.13%
Mar 2026 $1.7B (15.94%)
Dec 2025 $2.0B 21.53%
Sep 2025 $1.6B 0.12%
42 more quarters

Against its own ten years

Low $2.0B High $7.7B
Ten-year median $6.0B
Current reading's percentile 82

Net income against peers

What Net income is

Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.

Reported line item

The full definition of Net income →

More on TMO